300 Third Street, First Floor
About Editas Medicine
Editas Medicine is a transformative genome editing company founded by world leaders in the fields of genome editing, protein engineering, and molecular and structural biology, with specific expertise in CRISPR/Cas9 and TALENs technologies.
The company's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.
Editas was founded in 2013 with $43 million in Series A venture capital financing led by leading health care venture capital firms Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund.
Founders: Feng Zhang, Jennifer Doudna, George Church, J. Keith Joung, and David Liu
CEO: Karine Bosley
CFO: Andrew Hack
COO: Alexandra Glucksmann
CTO: Vic Myer
Please click here for Editas Medicine job opportunities.
FOLLOW EDITAS MEDICINE:
Tweets by Editas Medicine
136 articles with Editas Medicine
Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory Officer
Editas Medicine, Inc. today announced the grant of inducement awards to the Company’s newly appointed Executive Vice President and Chief Scientific Officer, Mark Shearman, Ph.D., and Senior Vice President and Chief Regulatory Officer, Chi Li, Ph.D.
Editas Medicine Strengthens Executive Leadership Team to Advance Pipeline and Support Long-term Growth
Editas Medicine, Inc. today announced that it named Chi Li, Ph.D., MBA, RAC, as the Company’s Senior Vice President and Chief Regulatory Officer, effective immediately.
Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association Congress
Editas Medicine, Inc., a leading genome editing company, announced preclinical data supporting the initiation of the EDIT-301 Phase 1/2 RUBY clinical trial to evaluate EDIT-301, a one-time, durable, autologous cell therapy medicine to treat sickle cell disease.
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Mark S. Shearman, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Shearman will join Editas Medicine in June 2021, and will lead drug discovery, research, and development for the Company’s pipeline of experimental medicines .
Strengthening Leadership by Adding Mark S. Shearman, Ph.D., as Chief Scientific Officer Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of EDIT-301 for sickle cell disease active and recruiting Preclinical ocular data presented at ARVO supports in vivo gene editing Cash, cash equivalents, and marketable securities of $723 million as of March 31, 2021
Editas Medicine to Present Preclinical Data Demonstrating Progress in Development of Gene Editing Medicines for the Treatment of Genetic Ocular Diseases at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine, Inc., a leading genome editing company, announced three presentations, including one from a research collaboration, at the American Society of Gene and Cell Therapy Annual Meeting being held virtually May 11 – 14, 2021.
Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases at the Association for Research in Vision and Ophthalmology Annual Meeting
Preclinical data support novel approaches for the treatment of Usher Syndrome 2A and retinitis pigmentosa 4
Editas Medicine, Inc., a leading genome editing company, announced that it will host a conference call and webcast on Wednesday, May 5, 2021, at 8:00 a.m. ET to discuss a corporate update and results for the first quarter of 2021.
Strengthened Leadership by Appointing James (Jim) C. Mullen as President and Chief Executive Officer, and Lisa A. Michaels, M.D., as Chief Medical Officer Appointed Meeta Chatterjee, Ph.D., to Board of Directors Initiated dosing of adult mid-dose cohort of BRILLIANCE trial of EDIT-101 for LCA10 Initiated Phase 1/2 RUBY trial for EDIT-301 for sickle cell disease Ended 2020 with strong cash position of $512 million, and raised additional $250 million in early 2021
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 25, 2021, at 8:00 a.m. ET to discuss a corporate update and results for the fourth quarter and full year of 2020.
James C. Mullen succeeds Cynthia Collins as Editas’ CEO, effective on February 15, 2021.
Editas Medicine Announces Appointment of James C. Mullen as Chief Executive OfficerCindy Collins to Step Down Effective February 15, 2021
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that James (Jim) C. Mullen will succeed Cynthia (Cindy) Collins as Chief Executive Officer, effective February 15, 2021
Editas Medicine, Inc., a leading gene editing company, announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses.
Editas Medicine, Inc., a leading gene editing company, announced that it intends to offer and sell 3,500,000 shares of its common stock in an underwritten public offering.
Provides EDIT-301 updates, including timeline for dosing sickle cell disease patients in the Phase 1/2 RUBY trial and plans to file IND for the treatment of beta-thalassemia
Editas Medicine, Inc., a leading genome editing company, announced that its Chief Scientific Officer, Charles Albright, Ph.D., is stepping down from the Company on January 15 to pursue another opportunity.
Editas Medicine Announces the FDA has Cleared Initiation of the EDIT-301 Clinical TrialEDIT-301 is in development as a best-in-class, durable medicine for people living with sickle cell disease
Editas Medicine, Inc., a leading genome editing company, announced the U.S. Food and Drug Administration has cleared the initiation of the safety phase of the Company’s EDIT-301 clinical trial, and the Company can begin dosing patients.
Editas Medicine, Inc., a leading genome editing company, announced that it will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, January 13, 2021, at 10:50 a.m. ET.
Female leaders in the biopharma industry may further promote diversity and inclusion at the workplace and serve as role models for young female professionals. Here is a list of 16 of the highest-paid female CEOs in biopharma.
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced it submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1/2 clinical trial of EDIT-301, an experimental CRISPR/Cas12a gene editing medicine in development for the treatment of sickle cell disease